Merrimack Pharmaceuticals Inc (NASDAQ:MACK)
| 5.11 Data as of May 22 |  -0.16 / -3.04%Today’s Change | 4.06 Today|||52-Week Range 11.11 | -16.09% Year-to-Date |
Latest MACK News | Press Releases
No recent news for Merrimack Pharmaceuticals Inc.
Today’s Trading
| Previous close | 5.27 |
| Today’s open | 5.32 |
| Day’s range | 5.01 - 5.47 |
| Volume | 281,351 |
| Average volume (3 months) | 328,191 |
| Market cap | $506.4M |
| Dividend yield | -- |
Data as of 4:00pm ET, 05/22/2013
Growth & Valuation
| Earnings growth (last year) | +82.04% |
| Earnings growth (this year) | +19.14% |
| Earnings growth (next 5 years) | -- |
| Revenue growth (last year) | +42.98% |
| P/E ratio | NM |
| Price/Sales | 9.07 |
| Price/Book | -- |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| ECYTEndocyte Inc | -0.44 | -3.09% |
| EBSEmergent BioSolution... | +0.04 | +0.28% |
| CMRXChimerix Inc | +0.27 | +1.34% |
| SNTASynta Pharmaceutical... | -0.12 | -1.60% |
Data as of 4:03pm ET, 05/22/2013
Financials
| Last reporting date | May 13, 2013 |
| EPS forecast (this quarter) | -$0.28 |
| Annual revenue (last year) | $48.9M |
| Annual profit (last year) | -$91.3M |
| Net profit margin | -186.58% |
Profile
Sector Health Technology |
Industry Biotechnology |
President, Chief Executive Officer & Director Robert J. Mulroy |
Senior Vice President- Operations William M. McClements, MBA |
Corporate headquarters Cambridge, Massachusetts |
Forecasts
